Fulcrum Therapeutics (FULC) Operating Leases (2022 - 2026)

Fulcrum Therapeutics (FULC) has reported Operating Leases for 5 consecutive years, with $2.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Operating Leases fell 47.71% year-over-year to $2.8 million; the TTM figure through Jun 2026 stood at $2.8 million (down 47.71% YoY), while the FY2025 annual figure was $4.0 million, down 37.31% from the prior year.
• Operating Leases eased to $2.8 million in Q2 2026 per FULC's latest filing, from $3.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $12.8 million in Q1 2022 and bottomed at $2.8 million in Q2 2026.
• Historically, Operating Leases has averaged $7.8 million across 5 years, with a median of $7.8 million in 2024.
• Annual changes were most pronounced in 2024 — Operating Leases slipped 20.05% — and 2026, when it sank 47.71%.
• Fulcrum Therapeutics' Operating Leases stood at $10.8 million in 2022, then decreased by 20.26% to $8.6 million in 2023, then decreased by 25.33% to $6.4 million in 2024, then plunged by 37.31% to $4.0 million in 2025, then slumped by 31.67% to $2.8 million in 2026.
• Business Quant data shows FULC's Operating Leases at $2.8 million in Q2 2026, $3.4 million in Q1 2026, and $4.0 million in Q4 2025.